ReviewCurrent medicinal chemistry2006
Telomerase inhibition in cancer therapeutics: molecular-based approaches.
Review in Current medicinal chemistry, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Telomerase reverse transcriptase degradation via a rationally designed covalent proteolysis targeting chimera.Bioorganic & medicinal chemistry letters · 2025Article
- P19 a Parthenin Analog Induces Cell Lineage Dependent Apoptotic and Immunomodulatory Signaling in Acute Lymphoid Leukemia Cells.International journal of molecular and cellular medicine · 2023Article
- Drug discovery of small molecules targeting the higher-order hTERT promoter G-quadruplex.PloS one · 2022Article
- The CINs of Polo-Like Kinase 1 in Cancer.Cancers · 2020Review
- The hTERT core promoter forms three parallel G-quadruplexes.Nucleic acids research · 2020Article
- Therapeutic Targets in Telomerase and Telomere Biology of Cancers.Indian journal of clinical biochemistry : IJCB · 2020Review
- Stilbene Compounds Inhibit Tumor Growth by the Induction of Cellular Senescence and the Inhibition of Telomerase Activity.International journal of molecular sciences · 2019Review
- New therapeutic strategies based on interference with telomeric DNA synthesis of tumor cells to suppress the growth of tumors.RSC advances · 2018Article
- RNA interference mediated downregulation of human telomerase reverse transcriptase (hTERT) in LN18 cells.Cytotechnology · 2016Article
- Telomerase as a Cancer Target. Development of New Molecules.Current topics in medicinal chemistry · 2016Review
- Inhibition of human telomerase reverse transcriptase in vivo and in vitro for retroviral vector-based antisense oligonucleotide therapy in ovarian cancer.Cancer gene therapy · 2016Article
- siRNA suppression of hTERT using activatable cell-penetrating peptides in hepatoma cells.Bioscience reports · 2015Article
- The transposon-driven evolutionary origin and basis of histone deacetylase functions and limitations in disease prevention.Clinical epigenetics · 2011Article
- A novel prodrug of epigallocatechin-3-gallate: differential epigenetic hTERT repression in human breast cancer cells.Cancer prevention research (Philadelphia, Pa.) · 2011Article
- Effects of a growth hormone-releasing hormone antagonist on telomerase activity, oxidative stress, longevity, and aging in mice.Proceedings of the National Academy of Sciences of the United States of America · 2010Article
- The retrovirus-mediated antisense human telomerase RNA (hTR) gene limits the growth of hepatocellular carcinoma growth in cell culture and animals.Digestive diseases and sciences · 2008Article
- Bladder cancer in the elderly.Urologic oncologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Current standard cancer therapies (chemotherapy and radiation) often cause serious adverse off-target effects. Drug design strategies are therefore being developed that will more precisely target cancer cells for destruction while leaving surrounding normal cells relatively unaffected. Telomerase, widely expressed in most human cancers but almost undetectable in normal somatic cells, provides an exciting drug target. This review focuses on recent pharmacogenomic approaches to telomerase inhibition. Antisense oligonucleotides, RNA interference, ribozymes, mutant expression, and the exploitation of differential telomerase expression as a strategy for targeted oncolysis are discussed here in the context of cancer therapeutics. Reports of synergism between telomerase inhibitors and traditional cancer therapeutic agents are also analyzed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.